Limits...
Real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.

Hagège H, Laugier R, Nahon S, Coulom P, Isnard-Bagnis C, Albert-Marty A - Endosc Int Open (2015)

Bottom Line: The purpose of this study was to describe the real-life conditions of use, efficacy, safety, and acceptability of sodium phosphate (NaP) tablets for colon cleansing in routine medical practice in France.Gastroscopy associated with colonoscopy in 38.9 % of the patients revealed gastric lesions, which were considered as possibly related to the use of NaP tablets in 10.3 % of them.The quality of colon cleansing and the safety and acceptability of NaP tablets were satisfactory and consistent with data from randomized clinical studies.

View Article: PubMed Central - PubMed

Affiliation: CHI de Créteil, Service d'Hépato-gastroentérologie, Créteil, France.

ABSTRACT

Background and study aims: The purpose of this study was to describe the real-life conditions of use, efficacy, safety, and acceptability of sodium phosphate (NaP) tablets for colon cleansing in routine medical practice in France.

Patients and methods: A total of 996 patients undergoing bowel preparation were enrolled by 108 gastroenterologists in this observational, longitudinal, prospective, multicenter study. The conditions of use of NaP tablets were assessed with a composite endpoint, which included six criteria for patient compliance with the recommended administration scheme and a criterion for the absence of contraindications to NaP use.

Results: Adequate use of NaP was reported for 75.1 % of the patients. The main reasons for misuse were a smaller fluid intake than expected with a dose of 4 tablets and noncompliance with age-related contraindications. The quality of cleansing was satisfactory: the Boston Bowel Preparation Scale (BBPS) total score was 7 or higher in 75.4 % of the patients. Gastroscopy associated with colonoscopy in 38.9 % of the patients revealed gastric lesions, which were considered as possibly related to the use of NaP tablets in 10.3 % of them. Vomiting occurred in 9.8 % of the patients, and 0.6 % discontinued bowel preparation after an adverse event. No electrolyte disorders or renal impairment was reported, even if not systematically sought. The acceptability of the NaP tablets was high, particularly among patients who previously had undergone other methods of bowel preparation.

Conclusions: Despite being defined according to strict criteria, adequate use of NaP tablets was observed in a high percentage of patients. The quality of colon cleansing and the safety and acceptability of NaP tablets were satisfactory and consistent with data from randomized clinical studies.

No MeSH data available.


Related in: MedlinePlus

Flow chart of the population analysis of patients in a study of the real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4554515&req=5

FI124-1: Flow chart of the population analysis of patients in a study of the real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.

Mentions: From September 2011 to March 2012, 1048 patients were included and 996 were analyzed; 926 were included in the population analysis for the primary endpoint (Fig. 1). The patients’ characteristics are described in Table 3. The most frequent concomitant diseases were related to the cardiovascular system (15.8 %); endocrine system/metabolism (15.8 %), including hypothyroidism (5.8 %) and diabetes mellitus (3.7 %); and gastrointestinal system (7.5 %). Furthermore, 56.7 % of the patients were receiving at least one concomitant treatment, the most frequent of which were cardiovascular treatments (39.3 %) and cholesterol-lowering agents (26.9 %).


Real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.

Hagège H, Laugier R, Nahon S, Coulom P, Isnard-Bagnis C, Albert-Marty A - Endosc Int Open (2015)

Flow chart of the population analysis of patients in a study of the real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4554515&req=5

FI124-1: Flow chart of the population analysis of patients in a study of the real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.
Mentions: From September 2011 to March 2012, 1048 patients were included and 996 were analyzed; 926 were included in the population analysis for the primary endpoint (Fig. 1). The patients’ characteristics are described in Table 3. The most frequent concomitant diseases were related to the cardiovascular system (15.8 %); endocrine system/metabolism (15.8 %), including hypothyroidism (5.8 %) and diabetes mellitus (3.7 %); and gastrointestinal system (7.5 %). Furthermore, 56.7 % of the patients were receiving at least one concomitant treatment, the most frequent of which were cardiovascular treatments (39.3 %) and cholesterol-lowering agents (26.9 %).

Bottom Line: The purpose of this study was to describe the real-life conditions of use, efficacy, safety, and acceptability of sodium phosphate (NaP) tablets for colon cleansing in routine medical practice in France.Gastroscopy associated with colonoscopy in 38.9 % of the patients revealed gastric lesions, which were considered as possibly related to the use of NaP tablets in 10.3 % of them.The quality of colon cleansing and the safety and acceptability of NaP tablets were satisfactory and consistent with data from randomized clinical studies.

View Article: PubMed Central - PubMed

Affiliation: CHI de Créteil, Service d'Hépato-gastroentérologie, Créteil, France.

ABSTRACT

Background and study aims: The purpose of this study was to describe the real-life conditions of use, efficacy, safety, and acceptability of sodium phosphate (NaP) tablets for colon cleansing in routine medical practice in France.

Patients and methods: A total of 996 patients undergoing bowel preparation were enrolled by 108 gastroenterologists in this observational, longitudinal, prospective, multicenter study. The conditions of use of NaP tablets were assessed with a composite endpoint, which included six criteria for patient compliance with the recommended administration scheme and a criterion for the absence of contraindications to NaP use.

Results: Adequate use of NaP was reported for 75.1 % of the patients. The main reasons for misuse were a smaller fluid intake than expected with a dose of 4 tablets and noncompliance with age-related contraindications. The quality of cleansing was satisfactory: the Boston Bowel Preparation Scale (BBPS) total score was 7 or higher in 75.4 % of the patients. Gastroscopy associated with colonoscopy in 38.9 % of the patients revealed gastric lesions, which were considered as possibly related to the use of NaP tablets in 10.3 % of them. Vomiting occurred in 9.8 % of the patients, and 0.6 % discontinued bowel preparation after an adverse event. No electrolyte disorders or renal impairment was reported, even if not systematically sought. The acceptability of the NaP tablets was high, particularly among patients who previously had undergone other methods of bowel preparation.

Conclusions: Despite being defined according to strict criteria, adequate use of NaP tablets was observed in a high percentage of patients. The quality of colon cleansing and the safety and acceptability of NaP tablets were satisfactory and consistent with data from randomized clinical studies.

No MeSH data available.


Related in: MedlinePlus